In a matter involving alleged abuse of the U.S. Pharmacopeia standard setting process, CRA examined market power for product dispensed through hospital and non-hospital sites of care. CRA’s expert found that in most uses, during the relevant time period there was ample evidence of competition, finding that the manufacturer at issue was effectively price constrained by existing competition.
Contested ground: Early competition and market dynamics in generative AI
CRA Competition experts, Andrea Asoni, Matteo Foschi, and Oliver Latham, teamed up with Chiara Farronato of Harvard Business School to reflect on developments...